Impact of treatment with recombinant human GH and IGF-I on visceral adipose tissue and glucose homeostasis in adults

Growth Hormone and IGF Research

Volumn 16, Issue SUPPL., 2006, Pages 55-61

  Yuen, Kevin C J ^a   Dunger, David B ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Growth hormone; Growth hormone deficient adults; Insulin sensitivity; Insulin like growth factor I; Metabolic syndrome

Indexed keywords

C PEPTIDE; FATTY ACID; GLUCOSE; GROWTH HORMONE; INSULIN; INSULIN SENSITIZING AGENT; PLACEBO; RECOMBINANT GROWTH HORMONE; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ACROMEGALY; ADULT; ARTICLE; BODY FAT DISTRIBUTION; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG DOSE REGIMEN; FEEDING; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE TRANSPORT; GROWTH HORMONE DEFICIENCY; HIGH RISK PATIENT; HORMONE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOGENESIS; LIPOLYSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE; GROWTH HORMONE; HORMONE REPLACEMENT THERAPY; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTRA-ABDOMINAL FAT; METABOLIC SYNDROME X;

EID: 33745215422     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2006.03.001     Document Type: Article

References (55)

1. Fowelin J., Attvall S., von Schenck H., et al. Characterization of the insulin-antagonistic effect of growth hormone in man. Diabetologia 34 (1991) 500-506
2. Fowelin J., Attval S., Lager I., et al. Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency. Metabolism 42 (1993) 1443-1447
3. Salomon F., Cuneo R.C., Hesp R., et al. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N. Engl. J. Med. 321 (1989) 1797-1803
4. Jones J.I., and Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 16 (1995) 3-34
5. Haluzik M., Yakar S., Gavrilova O., et al. Insulin resistance in the liver-specific IGF-1 gene-deleted mouse is abrogated by deletion of the acid-labile subunit of the IGF-binding protein-3 complex: relative roles of growth hormone and IGF-1 in insulin resistance. Diabetes 52 (2003) 2483-2489
6. Yakar S., Liu J.L., Fernandez A.M., et al. Liver-specific IGF-I gene deletion leads to muscle insulin insensitivity. Diabetes 50 (2001) 1110-1118
7. Yakar S., Setser J., Zhao H., et al. Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J. Clin. Invest. 113 (2004) 96-105
8. Houssay B.A. The hypophysis and metabolism. N. Engl. J. Med. 214 (1936) 961-986
9. Dunshea F.R., Boisclair Y.R., Bauman D.E., et al. Effects of bovine somatotropin and insulin on whole-body and hindlimb glucose metabolism in growing steers. J. Animal Sci. 73 (1995) 2263-2271
10. Rosenfeld R.G., Wilson D.M., Dollar L.A., et al. Both human pituitary growth hormone and recombinant DNA-derived human growth hormone cause insulin resistance at a postreceptor site. J. Clin. Endocrinol. Metab. 54 (1982) 1033-1038
11. Adamson U. On the diabetogenic effect of growth hormone in man: effects of growth hormone on glucagon and insulin secretion. Eur. J. Clin. Invest. 11 2 Suppl. 1 (1981) 115-119
12. Rizza R.A., Mandarino L.J., and Gerich J.E. Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization. Diabetes 31 (1982) 663-669
13. Randle P.R., Garland P.B., Hales C.N., et al. The glucose fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1 (1963) 785-789
14. Davidson M.B., and Bernstein J.M. The effect of nicotinic acid on growth hormone-induced lipolysis and glucose intolerance. J. Lab. Clin. Med. 81 (1975) 568-576
15. Dominici F.P., and Turyn D. Growth hormone-induced alterations in the insulin-signaling system. Exp. Biol. Med. (Maywood) 227 (2002) 149-157
16. Davidson M.B. Effect of growth hormone on carbohydrate and lipid metabolism. Endocr. Rev. 8 (1987) 115-131
17. Press M. Growth hormone and metabolism. Diabetes Metab. Rev. 4 (1988) 391-414
18. Pierluissi J., and Campbell J. Metasomatotrophic diabetes and its induction: basal insulin secretion and insulin release responses to glucose, glucagon, arginine and meals. Diabetologia 18 (1980) 223-228
19. Hansen A.P., and Johansen K. Diurnal patterns of blood glucose, serum free fatty acids, insulin, glucagon and growth hormone in normals and juvenile diabetics. Diabetologia 6 (1970) 27-33
20. Press M., Tamborlane W.V., and Sherwin R.S. Importance of raised growth hormone levels in mediating the metabolic derangements of diabetes. N. Engl. J. Med. 310 (1984) 810-815
21. Moller N., Schmitz O., Moller J., et al. Effects of a physiological growth hormone pulse on substrate metabolism in insulin-dependent (type 1) diabetic subjects. J. Clin. Endocrinol. Metab. 75 (1992) 432-436
22. Pal B.R., Matthews D.R., Edge J.A., et al. The frequency and amplitude of growth hormone secretory episodes as determined by deconvolution analysis are increased in adolescents with insulin dependent diabetes mellitus and are unaffected by short-term euglycaemia. Clin. Endocrinol. (Oxf.) 38 (1993) 93-100
23. Pal B.R., Phillips P.E., Matthews D.R., et al. Contrasting metabolic effects of continuous and pulsatile growth hormone administration in young adults with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 35 (1992) 542-549
24. Ho K.Y., Veldhuis J.D., Johnson M.L., et al. Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. J. Clin. Invest. 81 (1988) 968-975
25. Guler H.P., Zapf J., and Froesch E.R. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N. Engl. J. Med. 317 (1987) 137-140
26. Turkalj I., Keller U., Ninnis R., et al. Effect of increasing doses of recombinant human insulin-like growth factor-I on glucose, lipid, and leucine metabolism in man. J. Clin. Endocrinol. Metab. 75 (1992) 1186-1191
27. Laager R., Ninnis R., and Keller U. Comparison of the effects of recombinant human insulin-like growth factor-I and insulin on glucose and leucine kinetics in humans. J. Clin. Invest. 92 (1993) 1903-1909
28. Humbel R.E. Insulin-like growth factors I and II. Eur. J. Biochem. 190 (1990) 445-462
29. Steele-Perkins G., Turner J., Edman J.C., et al. Expression and characterization of a functional human insulin-like growth factor I receptor. J. Biol. Chem. 263 (1988) 11486-11492
30. Ullrich A., Gray A., Tam A.W., et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 5 (1986) 2503-2512
31. Baxter R.C., and Martin J.L. Binding proteins for the insulin-like growth factors: structure, regulation and function. Prog. Growth Factor Res. 1 (1989) 49-68
32. Frystyk J., Hojlund K., Rasmussen K.N., et al. Development and clinical evaluation of a novel immunoassay for the binary complex of IGF-I and IGF-binding protein-1 in human serum. J. Clin. Endocrinol. Metab. 87 (2002) 260-266
33. Frystyk J., Hussain M., Skjaerbaek C., et al. The pharmacokinetics of free insulin-like growth factor-I in healthy subjects. Growth Horm. IGF Res. 9 (1999) 150-156
34. Camacho-Hubner C., Woods K.A., Clark A.J., et al. Insulin-like growth factor (IGF)-I gene deletion. Rev. Endocr. Metab. Disord. 3 (2002) 357-361
35. Dunger D.B., and Cheetham T.D. Growth hormone insulin-like growth factor I axis in insulin-dependent diabetes mellitus. Horm. Res. 46 (1996) 2-6
36. Crowne E.C., Samra J.S., Cheetham T., et al. Recombinant human insulin-like growth factor-I abolishes changes in insulin requirements consequent upon growth hormone pulsatility in young adults with type I diabetes mellitus. Metabolism 47 (1998) 31-38
37. Acerini C.L., Harris D.A., Matyka K.A., et al. Effects of low-dose recombinant human insulin-like growth factor-I on insulin sensitivity, growth hormone and glucagon levels in young adults with insulin-dependent diabetes mellitus. Metabolism 47 (1998) 1481-1489
38. Simpson H.L., Jackson N.C., Shojaee-Moradie F., et al. Insulin-like growth factor I has a direct effect on glucose and protein metabolism, but no effect on lipid metabolism in type 1 diabetes. J. Clin. Endocrinol. Metab. 89 (2004) 425-432
39. Kern P.A., Svoboda M.E., Eckel R.H., et al. Insulinlike growth factor action and production in adipocytes and endothelial cells from human adipose tissue. Diabetes 38 (1989) 710-717
40. Kunitomi M., Wada J., Takahashi K., et al. Relationship between reduced serum IGF-I levels and accumulation of VAT in Japanese men. Int. J. Obes. Relat. Metab. Disord. 26 (2002) 361-369
41. Kaji H., Ohashi S., Abe H., et al. Regulation of the growth hormone (GH) receptor and GH-binding protein mRNA. Proc. Soc. Exp. Biol. Med. 206 (1994) 257-262
42. Pijl H., Langendonk J.G., Burggraaf J., et al. Altered neuroregulation of GH secretion in viscerally obese premenopausal women. J. Clin. Endocrinol. Metab. 86 (2001) 5509-5515
43. Yuen K., Frystyk J., Umpleby M., et al. Changes in free rather than total insulin-like growth factor-I enhance insulin sensitivity and suppress endogenous peak growth hormone (GH) release following short-term low-dose GH administration in young healthy adults. J. Clin. Endocrinol. Metab. 89 (2004) 3956-3964
44. Simpson H., Savine R., Sonksen P., et al. Growth hormone replacement therapy for adults: into the new millennium. Growth Horm. IGF Res. 12 (2002) 1-33
45. Hana V., Silha J.V., Justova V., et al. The effects of GH replacement in adult GH-deficient patients: changes in body composition without concomitant changes in the adipokines and insulin resistance. Clin. Endocrinol. (Oxf.) 60 (2004) 442-450
46. Weaver J.U., Monson J.P., Noonan K., et al. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults. J. Clin. Endocrinol. Metab. 80 (1995) 153-159
47. O'Neal D.N., Kalfas A., Dunning P.L., et al. The effect of 3 months of recombinant human growth hormone (GH) therapy on insulin and glucose-mediated glucose disposal and insulin secretion in GH-deficient adults: a minimal model analysis. J. Clin. Endocrinol. Metab. 79 (1994) 975-983
48. Svensson J., Fowelin J., Landin K., et al. Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J. Clin. Endocrinol. Metab. 87 (2002) 2121-2127
49. K. Yuen, D.K. White, V.K. Chatterjee, et al., Improved insulin sensitivity and quality of life without alterations in body composition in growth hormone deficient adults following 12 months of fixed low dose growth hormone administration, in: Presented at 86th Annual Meeting of the Endocrine Society, New Orleans, LA, 2004.
50. Sandhu M.S., Heald A.H., Gibson J.M., et al. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 359 (2002) 1740-1745
51. Juul A., Scheike T., Davidsen M., et al. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 106 (2002) 939-944
52. Johannsson G., Marin P., Lonn L., et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J. Clin. Endocrinol. Metab. 82 (1997) 727-734
53. Franco C., Brandberg J., Lonn L., et al. Growth hormone treatment reduces abdominal VAT in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial. J. Clin. Endocrinol. Metab. 90 (2005) 1466-1474
54. Santomauro A.T., Boden G., Silva M.E., et al. Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 48 (1999) 1836-1841
55. Yuen K., Wareham N., Frystyk J., et al. Short-term low-dose growth hormone administration in subjects with impaired glucose tolerance and the metabolic syndrome: effects on beta-cell function and post-load glucose tolerance. Eur. J. Endocrinol. 151 (2004) 39-45